Skip to content

Inside Kyron.bio’s Bold Bet to Rewrite the Rules of Antibody Drug Design

For all the buzz around antibody therapies, one overlooked culprit keeps holding them back: sugars. Paris-based Kyron.bio is tackling the hidden complexity of glycosylation — the way sugars attach to therapeutic proteins — with a platform that promises safer, longer-lasting drugs.

Kryon bio team

This post is for paying subscribers only

Subscribe

Already have an account? Sign In

Latest

🐇 Follow Me Down The Voice AI Rabbit Hole 🎤
AI

🐇 Follow Me Down The Voice AI Rabbit Hole 🎤

Voice AI has crossed the uncanny valley, turning sound, speech, and music into powerful tools. It’s fun, unsettling, and wildly investable. Welcome to the hottest, weirdest market in AI, where France is making some noise.

Members Public